0001109354 false 0001109354 2020-01-12 2020-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): January 13, 2020



(Exact name of registrant as specified in its charter)


Delaware   000-30833   04-3110160
(State or other jurisdiction of   Commission File No.   (I.R.S. Employer
Incorporation or organization)       Identification No.)


40 Manning Road

Billerica, MA 01821

(Address of principal executive offices) (Zip Code)



(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:


¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share   BRKR   The Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company  ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 2.02 Results of Operations and Financial Condition.


On January 13, 2020, during the scheduled presentation at the 38th Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) will state that it expects fiscal year 2019 organic revenue growth to be at or near the high end of the Company’s prior organic growth guidance range.


Because the Company’s financial statements for the fiscal year ended December 31, 2019 have not yet been finalized or audited, the preliminary statement regarding the Company’s expectations regarding its fiscal year 2019 organic revenue growth included in this Item 2.02 is subject to change, and the Company’s actual organic revenue growth for this period may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.


Item 7.01 Regulation FD Disclosure.


The information set forth in Item 2.02 of this Current Report is incorporated into this Item 7.01 by reference.


The information furnished in Item 2.02 and Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.


Forward Looking Statements


Any statements contained in this Current Report on Form 8-K that do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding management’s expectations regarding our fiscal year 2019 performance, including our organic revenue growth. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the preliminary nature of the Company’s fiscal year 2019 financial information, which is subject to completion of the Company’s year-end-audit, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2018. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 Date: January 13, 2020 By: /s/GERALD N. HERMAN
    Gerald N. Herman
    Chief Financial Officer



Jan. 13, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 13, 2020
Entity File Number 000-30833
Entity Registrant Name BRUKER CORPORATION
Entity Central Index Key 0001109354
Entity Tax Identification Number 04-3110160
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 40 Manning Road
Entity Address, City or Town Billerica
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01821
City Area Code 978
Local Phone Number 663-3660
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol BRKR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false